Patrick Finn compensation by year
Twist Bioscience Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $352,917 | $417,917 | $427,000 | $456,000 | $470,000 | $500,000 | $563,000 |
| Bonus | $0 | $0 | $0 | $0 | $123,761 | $0 | $0 |
| Stock awards | $1,039,793 | $774,968 | $0 | $1,888,673 | $4,283,916 | $2,762,157 | $6,748,947 |
| Option awards | $1,415,209 | $1,407,728 | $0 | $0 | — | $0 | $0 |
| Non-equity incentive | $205,764 | $225,120 | $240,668 | $272,506 | $230,039 | $465,000 | $583,592 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | — | $0 | $0 |
| All other | $0 | $50,646 | $58,683 | $73,273 | $120,142 | $127,394 | $127,403 |
| Total | $3,013,683 | $2,876,379 | $726,351 | $2,690,452 | $5,227,858 | $3,854,551 | $8,022,942 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Twist Bioscience Corp DEF 14A filed January 6, 2026, accession 0001581280-26-000006, and prior-year filings.
How this page was built: the Twist Bioscience Corp filed document, accession 0001581280-26-000006. Every figure is read from that document and cited to the page and table it appears in. Filed January 6, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 79,785 | $2,245,150 | — |
| PSU | 75,089 | $2,113,004 | — |
| PSU | 44,883 | $1,263,008 | — |
| PSU | 43,578 | $1,226,285 | — |
| PSU | 18,000 | $506,520 | — |
| PSU | 16,373 | $460,736 | — |
| PSU | 14,131 | $397,646 | — |
| PSU | 11,090 | $312,073 | — |
| PSU | 9,572 | $269,356 | — |
| PSU | 379 | $10,665 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Twist Bioscience Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Twist Bioscience’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Emily Leproust | Chief Executive Officer and Chair of the Board | $13,781,570 |
| Patrick Finn · this page | President and Chief Operating Officer | $8,022,942 |
| Adam Laponis | Chief Financial Officer | $4,216,117 |
| Dennis Cho | Chief Legal Officer and Corporate Secretary | $3,621,076 |
| Paula Green | Senior Vice President of Human Resources | $3,348,859 |
Patrick Finn's compensation dossier, Twist Bioscience
You have read Patrick Finn's totals and holdings. The dossier adds each equity grant Twist Bioscience disclosed for Patrick Finn and Twist Bioscience's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Twist Bioscience compensation record
free company briefThis page is one person within Twist Bioscience's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Twist Bioscience proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Twist Bioscience's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Twist Bioscience's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.